• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Abbott begins Voyager trial of its Encantor TAVI system and Leerink upgrades the stock

FinanceInternationalTradingViewAI summary
Image: TradingView

Abbott (ABT) began the Voyager trial to evaluate its Encantor TAVI system, software-guided and investigational, for aortic stenosis, and a pivotal U.S. trial is expected to start in the coming months. In addition, Leerink Partners upgraded Abbott from market perform to outperform and set a $124 price target, 18.7% above its November 18 close of $104.48.

In 30 seconds

  • Abbott began the Voyager trial to evaluate its Encantor TAVI system, software-guided and investigational, for aortic stenosis.
  • A pivotal U.S. trial is expected to start in the coming months.
  • Leerink Partners upgraded Abbott from market perform to outperform.
Read the full story at TradingView

IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading